(Q37643985)

21 August 2017

1 reference

title

Evolving novel anti-HER2 strategies (English)

1 reference

21 August 2017

Kellie L Jones

1

1 reference

PubMed ID

19959074

21 August 2017

Aman U Buzdar

series ordinal

2

1 reference

21 August 2017

1 December 2009

1 reference

Lancet Oncology Commission

21 August 2017

1 reference

21 August 2017

10

1 reference

21 August 2017

1179-1187

1 reference

21 August 2017

12

1 reference

HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors

21 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Lapatinib: current status and future directions in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Targeted cancer therapy: conferring specificity to cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

HER-2-positive metastatic breast cancer: trastuzumab and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Cancer vaccines: between the idea and the reality

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Targeted therapies in breast cancer: where are we now?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970315-8

7 January 2021

10.1016/S1470-2045(09)70315-8

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19959074